Strikingly, although primary tumours originated from every astrocyte batch invariably displayed Zfp423 downregulation, they did so to different extents, with AstroEGFR*1 and AstroEGFR*3 showing a greater reduction than AstroEGFR*2 (Fig. 4d), thus confirming results from human data and validating this model as a sensitive system to test the physiopathologically relevant role of Zfp423. This evidence concerns the gene ZNF423 and neoplasm.